Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Shares Outstanding (Weighted Average) (2017 - 2025)

Historic Shares Outstanding (Weighted Average) for Myriad Genetics (MYGN) over the last 13 years, with Q3 2025 value amounting to $93.1 million.

  • Myriad Genetics' Shares Outstanding (Weighted Average) rose 242.02% to $93.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.1 million, marking a year-over-year increase of 242.02%. This contributed to the annual value of $90.6 million for FY2024, which is 942.03% up from last year.
  • Latest data reveals that Myriad Genetics reported Shares Outstanding (Weighted Average) of $93.1 million as of Q3 2025, which was up 242.02% from $92.5 million recorded in Q2 2025.
  • Myriad Genetics' Shares Outstanding (Weighted Average)'s 5-year high stood at $93.1 million during Q3 2025, with a 5-year trough of $76.0 million in Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $81.7 million (2023), whereas its average is $84.1 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first skyrocketed by 148.7% in 2023, then skyrocketed by 1098.9% in 2024.
  • Quarter analysis of 5 years shows Myriad Genetics' Shares Outstanding (Weighted Average) stood at $78.0 million in 2021, then rose by 3.33% to $80.6 million in 2022, then rose by 2.73% to $82.8 million in 2023, then increased by 9.42% to $90.6 million in 2024, then rose by 2.76% to $93.1 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $93.1 million in Q3 2025, compared to $92.5 million in Q2 2025 and $91.4 million in Q1 2025.